New findings from a Biogen and Eisai clinical trial reveal that the companies’ Alzheimer’s therapy, lecanemab, can slow cognitive decline. The news is promising for Seattle-based AltPep, which is seeking to detect and treat the disease through similar methods.
In a study of 1,800 adults with mild cognitive impairment or mild Alzheimer’s, the new treatment decreased clinical deterioration by 27% after 18 months in comparison to a placebo. The FDA is anticipated to decide on lecanemab’s accelerated approval in January.
Seattle companies like AltPep and Athira Pharma are taking novel approaches to diagnosing and combatting the disease, and positive clinical trials like Biogen and Eisai’s support the larger Alzheimer’s research industry.
“We see the positive results reported for lecanemab as supportive of our approach,” said AltPep founder and CEO Valerie Daggett.